Canada-based drugmaker Bellus Health (TSX: BLU) has amended its agreement to acquire fellow Canadian company Thallion Pharmaceuticals (TSX: TLN) to appease Thallion’s largest shareholder.
The original acquisition was for around C$6.33 million ($6.02 million) in cash or C$0.1765 per share (on a fully-diluted basis) with the issue of contingent value rights (CVRs) to entitle the holders to additional payments of up to about C$7.66 million, or C$0.2135 per CVR, if product revenue milestones are achieved. But Jaguar Financial, Thallion’s largest single shareholder (10.1%), indicated it would vote against the deal unless CVR terms were significantly raised ( The Pharma Letter July 1).
Terms amended to remove C$10 million threshold
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze